Ratings Alnylam Pharmaceuticals, Inc. BOERSE MUENCHEN

Equities

DUL

US02043Q1076

Market Closed - BOERSE MUENCHEN Other stock markets 20:43:45 28/06/2024 BST			5-day change	1st Jan Change
227.5 ^EUR	-1.34%		+46.77%	+28.53%

06-28	UBS Adjusts Price Target on Alnylam Pharmaceuticals to $288 From $253, Maintains Buy Rating	MT
06-27	Stifel Adjusts Price Target on Alnylam Pharmaceuticals to $295 From $215, Maintains Buy Rating	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
The company is in a robust financial situation considering its net cash and margin position.
Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
For the past twelve months, EPS forecast has been revised upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
The company's "enterprise value to sales" ratio is among the highest in the world.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the past year, analysts have significantly revised downwards their profit estimates.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
ALNYLAM PHARMACEUTICALS, INC.	+28.53%	30.74B	-
MODERNA, INC.	+19.41%	45.51B	B-
IQVIA HOLDINGS INC.	-8.62%	38.52B	B
LONZA GROUP AG	+38.65%	38.13B	A
CELLTRION, INC.	-13.50%	26.03B	C
ICON PUBLIC LIMITED COMPANY	+10.74%	25.92B	B-
UNITED THERAPEUTICS CORPORATION	+44.87%	14.13B	B+
MEDPACE HOLDINGS, INC.	+34.36%	12.73B	C+
BIO-TECHNE CORPORATION	-7.14%	11.29B	B+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-12.61%	10.64B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes